- Trials with a EudraCT protocol (76)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
76 result(s) found for: Body cavity.
Displaying page 1 of 4.
EudraCT Number: 2016-004255-70 | Sponsor Protocol Number: 205687 | Start Date*: 2017-05-29 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Ltd | |||||||||||||
Full Title: A randomised, double-blind, parallel group PhIII study to assess the clinical efficacy and safety of 100 mg SC Mepolizumab as an add on to maintenance treatment in adults with severe bilateral nasa... | |||||||||||||
Medical condition: Treatment of nasal polyposis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) SE (Completed) NL (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001724-22 | Sponsor Protocol Number: GA39688 | Start Date*: 2017-12-21 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | |||||||||||||
Medical condition: Chronic rhinosinusitis with nasal polyps | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) CZ (Completed) PT (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003450-16 | Sponsor Protocol Number: WA40169 | Start Date*: 2018-06-04 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: OPEN-LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | |||||||||||||
Medical condition: Chronic rhinosinusitis with nasal polyps | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) PT (Completed) FI (Completed) CZ (Completed) BE (Completed) DE (Completed) HU (Completed) ES (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001718-28 | Sponsor Protocol Number: GA39855 | Start Date*: 2018-02-19 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS | |||||||||||||
Medical condition: Chronic rhinosinusitis with nasal polyps | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Completed) ES (Completed) FI (Completed) PL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019952-35 | Sponsor Protocol Number: CS001P3 | Start Date*: 2010-09-14 |
Sponsor Name:CEL-SCI Corporation | ||
Full Title: A Phase III, Open-label, Randomized, Multi-center Study of the Effects of Leukocyte Interleukin, Injection [Multikine] Plus Standard of Care (Surgery + Radiotherapy or Surgery + Concurrent Chemorad... | ||
Medical condition: Subjects with Advanced Primary Sqamous Cell Carcinoma of the oral Cavity/Soft Palate | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) PL (Completed) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) RO (Ongoing) HR (Completed) ES (Prematurely Ended) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-003226-33 | Sponsor Protocol Number: 0480 | Start Date*: 2018-09-13 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Dean of the Medical Faculty of the Friedrich-Alexander University Erlangen-Nürnberg Prof. Dr. Markus Neurath | |||||||||||||||||||||||||||||||||||||||||||
Full Title: First-line treatment of locally advanced HNSCC with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T cell infiltration (CheckRad-CD8) | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Locally advanced head and neck squamous cell carcinoma (HNSCC) | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-003833-24 | Sponsor Protocol Number: AGMT_HNO_PN | Start Date*: 2016-06-30 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:AGMT – Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Randomized phase III study: Supplemental parenteral nutrition for patients with locally advanced inoperable tumors of the head and neck, receiving definitive radiotherapy with Cetuximab or Cisplatin | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Locally advanced inoperable tumors of the head and neck under definitive radiotherapy with Cetuximab or Cisplatin | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: AT (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-000133-31 | Sponsor Protocol Number: AGO/2017/001 | Start Date*: 2017-07-31 |
Sponsor Name:UZ Gent | ||
Full Title: Combined hypofractionated stereotactic body radiotherapy with immunomodulating systemic therapy for inoperable recurrent head and neck cancer: detection of the maximum tolerated dose. | ||
Medical condition: local, regional or combined locoregional recurrence of squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx in previously irradiated tissue, with former irradiation with cu... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-002016-28 | Sponsor Protocol Number: 20040118 | Start Date*: 2005-01-04 | |||||||||||
Sponsor Name:Amgen | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduct... | |||||||||||||
Medical condition: Oral mucositis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) AT (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006521-30 | Sponsor Protocol Number: LTS10036 | Start Date*: 2007-09-26 | |||||||||||
Sponsor Name:sanofi-aventis recherche & développement | |||||||||||||
Full Title: Long term safety and tolerability of satavaptan in patients with cirrhosis of the liver that have been previously randomized and completed treatment in any of the phase III studies: EFC4492; EFC449... | |||||||||||||
Medical condition: Cirrhotic ascites | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) FR (Completed) BE (Completed) SE (Completed) DE (Prematurely Ended) ES (Completed) IT (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) PT (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000577-36 | Sponsor Protocol Number: S60379 | Start Date*: 2018-08-27 |
Sponsor Name:University Hospitals Leuven | ||
Full Title: Durvalumab (MEDI4736) plus tremelimumab in resectable, locally advanced squamous cell carcinoma of the oral cavity: a window of opportunity study | ||
Medical condition: resectable, locally advanced squamous cell carcinoma of the oral cavity | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004907-22 | Sponsor Protocol Number: AUG117150 | Start Date*: 2016-08-03 |
Sponsor Name:Medicines Development (Infectious Diseases) | ||
Full Title: A multicenter, open-label study to assess the efficacy and safety of potassium clavulanate/amoxicillin (CVA/AMPC 1:14 combination) in the treatment of [Japanese] children with acute bacterial rhin... | ||
Medical condition: Acute Bacterial Rhinosinusitis | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2017-003240-20 | Sponsor Protocol Number: 16-058 | Start Date*: 2017-10-12 |
Sponsor Name:RWTH Aachen, represented by the rector, himself represented by the dean of the Medical Faculty | ||
Full Title: Velphoro and impact on the oral cavity and gut microbiome | ||
Medical condition: Hyperphosphatemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2018-004139-66 | Sponsor Protocol Number: AGO/2018/006 | Start Date*: 2019-04-11 |
Sponsor Name:Ghent University Hospital | ||
Full Title: Effect of norepinephrine infusion on hepatic blood flow during goal-directed hemodynamic therapy. | ||
Medical condition: hepatic blood flow hepatic vascular pressures | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-000213-35 | Sponsor Protocol Number: 20020402 | Start Date*: 2005-08-05 | |||||||||||
Sponsor Name:Swedish Orphan Biovitrum AB (publ.) | |||||||||||||
Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduct... | |||||||||||||
Medical condition: Oral mucositis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) AT (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004202-60 | Sponsor Protocol Number: CER-001-SEP_AKI_01 | Start Date*: 2021-01-13 | |||||||||||
Sponsor Name:CERENIS THERAPEUTICS | |||||||||||||
Full Title: A RAndomized pilot study comparing short-term CER-001 infusions at different doses to prevent Sepsis-induced acute kidney injury | |||||||||||||
Medical condition: Sepsis due to intra-abdominal cavity infection or urosepsis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015578-37 | Sponsor Protocol Number: BAY12-8039/11643 | Start Date*: 2010-05-10 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: A randomized, double-blind, multicenter trial to evaluate the safety and efficacy of sequential (intravenous, oral) moxifloxacin versus comparator in pediatric subjects with complicated intraabdomi... | |||||||||||||
Medical condition: Complicated intra-abdominal infections (cIAI) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Prematurely Ended) LV (Completed) LT (Completed) CZ (Completed) BE (Prematurely Ended) HU (Completed) BG (Completed) GR (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003702-41 | Sponsor Protocol Number: IDR-OM-02 | Start Date*: 2018-07-03 |
Sponsor Name:Soligenix UK Limited | ||
Full Title: A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for... | ||
Medical condition: Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) FR (Ongoing) ES (Completed) HU (Completed) PL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004248-39 | Sponsor Protocol Number: PPI-microbiome | Start Date*: 2018-01-04 |
Sponsor Name:TARGID, KU Leuven | ||
Full Title: Effect of Proton Pump Inhibitors on the duodenal microbiome in healthy volunteers | ||
Medical condition: We will assess the effect of Proton Pump Inhibitors (PPI) on the duodenal, oral and fecal microbiota composition in healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-004398-22 | Sponsor Protocol Number: 1 | Start Date*: 2013-07-01 |
Sponsor Name:Afd. A, OUH | ||
Full Title: intraperitoneal microdialysis after server peritonitis | ||
Medical condition: server peritonitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
